28 Oct ober 2026 ASX RELEASE QUARTERLY ACTIVITIES AND CASH FLOW REPORTS – September 2026 Key Highlights from the Quarter • The ACCENT trial in pancreatic cancer nears completion with promising data continuing to be recorded • A collaboration with Eli Lilly, the world’s largest...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Receives R&D Tax Rebate Totalling $4.78 Million
- Response to ASX Price Query
- Amplia signs Collaboration and Supply Agreement with Lilly
- Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
- Amplia Announces Publication of New FAK Inhibitor Patent Application
